Erasca ERAS
NASDAQ ERAS
$16.16 -0.10 (-0.62%)
As of: Sep 4, 2026 · 12:50 PM EDT

Erasca (ERAS) Research & Development (2020 - 2026)

Erasca's (ERAS) quarterly Research & Development came in at $27.3 million in Q1 2026, up 4.99% YoY from $26.0 million in Q1 2025, and up 17.31% on a QoQ basis from $23.2 million in Q4 2025.

Analysis

Erasca (ERAS) Research & Development (2020 - 2026) Analysis & Trends

Erasca (ERAS) has 7 years of Research & Development data on file, last reported at $27.3 million in Q1 2026.

  • Quarterly Research & Development rose 4.99% year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.1 million (down 16.5% YoY) and the FY2025 annual result came in at $92.9 million, down 19.51% from the prior year.
  • Research & Development advanced to $27.3 million in Q1 2026, from $23.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $33.0 million in Q2 2024 to a low of $21.2 million in Q2 2025.
  • A 5-year average of $26.6 million and a median of $27.3 million in 2026 frame the typical range for Research & Development.
  • Annual changes were most pronounced in 2022 — Research & Development jumped 124.0% — and 2025, when it plunged 35.91%.
  • Tracing ERAS's Research & Development over 5 years: stood at $29.4 million in 2022, then declined by 15.5% to $24.8 million in 2023, then gained by 5.31% to $26.1 million in 2024, then fell by 11.03% to $23.2 million in 2025, then grew by 17.31% to $27.3 million in 2026.
  • The last three Research & Development figures came in at $27.3 million (Q1 2026), $23.2 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn 993.80 Mn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn 1.63 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn -486.00 Mn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn 651.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - 394.92 Mn
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn 612.28 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn 413.13 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn - 97.90 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn 210.03 Mn
10 Erasca 5.03 Bn 5.03 Bn - 35.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 35.90 Mn
Mar 31, 2026 27.27 Mn
Dec 31, 2025 23.24 Mn
Sep 30, 2025 22.47 Mn
Jun 30, 2025 21.17 Mn
Mar 31, 2025 25.97 Mn
Dec 31, 2024 26.12 Mn
Sep 30, 2024 27.63 Mn
Jun 30, 2024 33.03 Mn
Mar 31, 2024 28.57 Mn
Dec 31, 2023 24.81 Mn
Sep 30, 2023 25.21 Mn
Jun 30, 2023 26.22 Mn
Mar 31, 2023 27.59 Mn
Dec 31, 2022 29.36 Mn
Sep 30, 2022 28.18 Mn
Jun 30, 2022 27.49 Mn
Mar 31, 2022 27.43 Mn
Dec 31, 2021 24.13 Mn
Sep 30, 2021 19.95 Mn